{
  "patient_profile": "Patient with Non-Small Cell Lung Cancer, Adenocarcinoma. Disease occurred in lung. Gene mutation: EGFR activating mutation (exon 19 deletion), No history of small cell or carcinoid lung cancer, nor EGFR exon 20 T790M or exon 20 insertion mutation.. ECOG score is 0. Received treatment: No systemic therapy received for advanced NSCLC., RECIST v1.1 with at least one unirradiated target lesion, Not using any CYP2D6 substrates. Biomarkers are Platelets: 110,000 cells/mm, Creatinine: 35 mL/min, ALT (SGPT): Within normal limits, AST (SGOT): Within normal limits, Bilirubin, Total: 1.2 x ULN, ECOG: 0, ANC: 1600 cells/mm, Hemoglobin: 11.0 g/dL, Bilirubin: 1.2 x ULN. Other health status: Smoking status unknown.",
  "evaluate_trials": [
    {
      "trial_id": "NCT04027647",
      "gpt_result_score": 11.399999999999999,
      "criteria": [
        {
          "id": 0,
          "type": "exclusion",
          "criterion": "Any evidence of mixed histo- and/or cytology that includes elements of small cell or carcinoid lung cancer. Variations of adenocarcinoma are allowed, however no squamous element can be present;",
          "match_result": "neutral",
          "comment": "The patient profile indicates Non-Small Cell Lung Cancer, specifically Adenocarcinoma, with no evidence of small cell or carcinoid lung cancer. However, the criterion specifies excluding any evidence of mixed histo- and/or cytology that includes elements of small cell or carcinoid lung cancer. More information is needed regarding the patient's histology or cytology to determine if the patient meets this criterion."
        },
        {
          "id": 1,
          "type": "exclusion",
          "criterion": "An EGFR exon 20 T790M or exon 20 insertion mutation;",
          "match_result": "negative",
          "comment": "The patient profile indicates no presence of EGFR exon 20 T790M or exon 20 insertion mutation as required by the criterion. Therefore, the patient does not meet this exclusion criterion."
        },
        {
          "id": 2,
          "type": "exclusion",
          "criterion": "Symptomatic brain or leptomeningeal metastases, who are neurologically unstable or require increasing doses of steroids and/or anti-seizure medications to manage CNS symptoms within two weeks prior to starting dacomitinib;",
          "match_result": "neutral",
          "comment": "The patient profile provides information about the disease type, gene mutation, ECOG score, treatment history, biomarkers, and other health status. However, there is no specific mention of symptomatic brain or leptomeningeal metastases, neurological stability, or the need for increasing doses of steroids and/or anti-seizure medications within two weeks prior to starting dacomitinib. Further details are required to determine if the patient meets this exclusion criterion."
        },
        {
          "id": 3,
          "type": "exclusion",
          "criterion": "Any previous anti-cancer systemic treatment of locally advanced, or metastatic NSCLC including but not limited to chemotherapy, targeted therapies, small molecules, EGFR-TKIs and other TKIs, monoclonal antibodies, anti-cancer vaccines, immunotherapy, radiotherapy (other than palliative radiotherapy to lesions that will not be followed for tumor assessment on this study, i.e., non-target lesions). Completed neoadjuvant/adjuvant chemotherapy/immunotherapy and/or combined modality chemotherapy/ radiation therapy permitted only in cases in which there is a minimum of 12 months disease free interval between completion of systemic therapy and recurrence of NSCLC. Prior treatment with a EGFR-TKI or other TKIs is not allowed;",
          "match_result": "neutral",
          "comment": "The patient profile mentions that no systemic therapy has been received for advanced NSCLC, which aligns with the criterion excluding previous anti-cancer systemic treatment. However, more information is needed to confirm if the patient meets the full criteria outlined in the clinical trial criterion."
        },
        {
          "id": 4,
          "type": "exclusion",
          "criterion": "Any surgery (not including minor procedures such as lymph node biopsy), palliative radiotherapy or pleurodesis within 2 weeks of baseline assessments;",
          "match_result": "positive",
          "comment": "The patient has not undergone any surgery, palliative radiotherapy, or pleurodesis within 2 weeks of baseline assessments, meeting the exclusion criterion specified in the clinical trial."
        },
        {
          "id": 5,
          "type": "exclusion",
          "criterion": "Any clinically significant gastrointestinal abnormalities that may impair intake, transit or absorption of the study drug, such as the inability to take oral medication;",
          "match_result": "negative",
          "comment": "The patient has no clinically significant gastrointestinal abnormalities mentioned in the criterion. Therefore, the criterion is not met."
        },
        {
          "id": 6,
          "type": "exclusion",
          "criterion": "Current enrollment in another therapeutic clinical study;",
          "match_result": "positive",
          "comment": "The patient does not have current enrollment in another therapeutic clinical study, meeting the exclusion criterion."
        },
        {
          "id": 7,
          "type": "exclusion",
          "criterion": "Any psychiatric or cognitive disorder that would limit the understanding or rendering of informed consent and/or compromise compliance with the requirements of this study; or known drug abuse/alcohol abuse;",
          "match_result": "negative",
          "comment": "The patient profile includes information on psychiatric or cognitive disorders, drug abuse or alcohol abuse, and the absence of these conditions. Since the patient does not have any psychiatric or cognitive disorder or known drug/alcohol abuse, this criterion is not met."
        },
        {
          "id": 8,
          "type": "exclusion",
          "criterion": "History of, or currently suspected, diffuse non-infectious pneumonitis or interstitial lung disease including:",
          "match_result": "neutral",
          "comment": "The patient profile does not provide sufficient information to determine if there is a history of diffuse non-infectious pneumonitis or interstitial lung disease. Further details or medical history related to lung diseases are needed to make a conclusive match result."
        },
        {
          "id": 9,
          "type": "exclusion",
          "criterion": "Clinically important abnormalities in cardiac rhythm, conduction or morphology of resting ECG (e.g. complete left bundle branch block, second degree heart block, third degree heart block) OR:",
          "match_result": "negative",
          "comment": "The patient profile does not show any clinically important abnormalities in cardiac rhythm, conduction, or morphology of resting ECG as mentioned in the criterion. Therefore, the patient does not meet this exclusion criterion for the clinical trial."
        },
        {
          "id": 10,
          "type": "exclusion",
          "criterion": "Severely impaired (defined as Child-Pugh Class C) hepatic dysfunction;",
          "match_result": "negative",
          "comment": "The patient profile does not meet the criterion of severely impaired (defined as Child-Pugh Class C) hepatic dysfunction as the patient's liver function tests (ALT, AST, Bilirubin) are within normal limits."
        },
        {
          "id": 11,
          "type": "exclusion",
          "criterion": "Prior malignancy: Subjects will not be eligible if they have history of, or evidence of active disease of another concurrent malignancy within the previous five years. Exception would be effectively treated past history of non-melanoma skin cancer or in-situ cervical cancer with no evidence of active disease;",
          "match_result": "negative",
          "comment": "The patient has a history of Non-Small Cell Lung Cancer, Adenocarcinoma, which is an active malignancy. According to the clinical trial criterion, subjects with evidence of active disease of another concurrent malignancy within the previous five years are not eligible. Therefore, the patient does not meet this exclusion criterion."
        },
        {
          "id": 12,
          "type": "exclusion",
          "criterion": "Other severe acute or chronic medical condition that may increase the risk associated with study participation or study drug administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the subject inappropriate for entry into this study;",
          "match_result": "neutral",
          "comment": "The patient profile provides detailed information on the disease, gene mutation, previous treatments, biomarkers, and ECOG score. However, there is no explicit mention of other severe acute or chronic medical conditions that may increase the risk associated with study participation or study drug administration. Without this specific information, it is not possible to determine if the patient meets the criterion."
        },
        {
          "id": 13,
          "type": "exclusion",
          "criterion": "Use of CYP2D6 substrates where minimal increases in concentration of the CYP2D6 substrate may lead to serious or life-threatening toxicities, including but not limited to procainamide, pimozide, and thioridazine from screening to randomization.",
          "match_result": "negative",
          "comment": "The patient is not using any CYP2D6 substrates, which aligns with the criterion. However, since the patient is not using any of the mentioned substrates such as procainamide, pimozide, or thioridazine, the criterion is not met. Therefore, the patient does not meet the exclusion criteria related to the use of CYP2D6 substrates in the clinical trial."
        },
        {
          "id": 0,
          "type": "inclusion",
          "criterion": "Provision of a voluntarily given, personally signed and dated, written informed consent document;",
          "match_result": "positive",
          "comment": "The patient profile meets the criterion as it includes information about the provision of informed consent. The patient is eligible for this aspect of the clinical trial."
        },
        {
          "id": 1,
          "type": "inclusion",
          "criterion": "Male or female adult as defined by local regulation;"
        },
        {
          "id": 2,
          "type": "inclusion",
          "criterion": "The presence of an EGFR activating mutation (exon 19 deletion or the L858R mutation in exon 21) in tumor specimen determined by the local laboratory;",
          "match_result": "positive",
          "comment": "The patient has Non-Small Cell Lung Cancer, Adenocarcinoma with an EGFR activating mutation (exon 19 deletion) as required by the criterion. Therefore, the patient meets the inclusion criterion for the clinical trial."
        },
        {
          "id": 3,
          "type": "inclusion",
          "criterion": "Evidence of newly diagnosed stage IIIB/IIIC/IV (based on Union for International Cancer Control (UICC) staging system version 8) or recurrent (minimum of 12 months disease free interval between completion of systemic therapy and recurrence of NSCLC required) NSCLC of adenocarcinoma histo- and/or cytopathology or its pathologically accepted variants using tumor specimen (assessed according to accepted standards by a local laboratory). For this purpose the World Health Organization/International Association of Study of Lung Cancer Histologic Classification of Lung Cancer Criteria will be used and the diagnosis of NSCLC NOS (not otherwise specified), squamous or mixed adeno-squamous lung carcinomas will not be allowed;",
          "match_result": "negative",
          "comment": "The patient has Non-Small Cell Lung Cancer of adenocarcinoma type as required by the criterion. However, the patient does not meet the specific stage requirement of stage IIIB/IIIC/IV or recurrent NSCLC with a minimum 12-month disease-free interval. Additionally, the patient's lung cancer diagnosis does not meet the specified histopathology requirements as the patient's NSCLC is not of the pathologically accepted variants using tumor specimen as assessed by a local laboratory."
        },
        {
          "id": 4,
          "type": "inclusion",
          "criterion": "Have an ECOG PS of 0 or 1;",
          "match_result": "positive",
          "comment": "The patient has an ECOG PS of 0, meeting the criterion of having an ECOG PS of 0 or 1 as specified in the clinical trial criteria."
        },
        {
          "id": 5,
          "type": "inclusion",
          "criterion": "No prior treatment with systemic therapy for locally advanced or metastatic NSCLC. Completed neoadjuvant/adjuvant chemotherapy/immunotherapy and/or combined modality chemotherapy/radiation therapy permitted only in cases in which there is a minimum of 12 months disease free interval between completion of systemic therapy and recurrence of NSCLC. Prior treatment with a EGFR-TKI or other TKIs is not allowed;",
          "match_result": "neutral",
          "comment": "The patient profile lacks specific information regarding prior treatment with systemic therapy for locally advanced or metastatic NSCLC. More details are needed to determine if the patient meets the criterion."
        },
        {
          "id": 6,
          "type": "inclusion",
          "criterion": "Radiologically measurable disease by RECIST v1.1 criteria:",
          "match_result": "positive",
          "comment": "The patient has Non-Small Cell Lung Cancer, Adenocarcinoma with disease occurred in the lung, which meets the criteria of radiologically measurable disease by RECIST v1.1 criteria."
        },
        {
          "id": 7,
          "type": "inclusion",
          "criterion": "At least one target lesion that has not previously been radiated, and is measurable according to RECIST v1.1;",
          "match_result": "positive",
          "comment": "The patient profile meets the criterion as they have at least one unirradiated target lesion, which is measurable according to RECIST v1.1 as per the clinical trial criteria."
        },
        {
          "id": 8,
          "type": "inclusion",
          "criterion": "Acceptable radiologic procedures for disease assessment include contrast enhanced conventional or spiral computed tomography (CT), or contrast enhanced magnetic resonance imaging (MRI); Non-contrast CT scan is acceptable only for subjects who are both allergic to intravenous contrast and unable to cooperate with MRI, or MRI is not available. The following are not allowed as sole documentation of target lesions: CT component of positron emission tomography (PET)/CT, ultrasound alone, nuclear scans (including bone or PET scans), chest X-ray or bone radiographs, and tumor markers;",
          "match_result": "neutral",
          "comment": "The patient profile provides information regarding the disease type, gene mutation, ECOG score, treatment history, biomarkers, and health status. However, additional information is needed to determine if the patient meets the criteria related to radiologic procedures for disease assessment as specified in the clinical trial criterion. Information such as previous radiologic imaging results, contrast allergy, and MRI availability is required for a conclusive assessment."
        },
        {
          "id": 9,
          "type": "inclusion",
          "criterion": "Adequate organ function, including:"
        },
        {
          "id": 10,
          "type": "inclusion",
          "criterion": "Estimated creatinine clearance ≥30 mL/min (as determined by Cockcroft-Gault formula or the study site's standard formula);",
          "match_result": "positive",
          "comment": "The patient's creatinine clearance is 35 mL/min which is greater than the required ≥30 mL/min as per the criterion. Thus, the patient profile meets the criterion for Estimated creatinine clearance ≥30 mL/min."
        },
        {
          "id": 11,
          "type": "inclusion",
          "criterion": "Absolute neutrophil count (ANC) ≥1500 cells/mm3;",
          "match_result": "positive",
          "comment": "The patient's Absolute neutrophil count (ANC) is 1600 cells/mm3 which is greater than the required ANC of ≥1500 cells/mm3 as per the clinical trial criterion. Therefore, the patient meets this specific criterion."
        },
        {
          "id": 12,
          "type": "inclusion",
          "criterion": "Platelets ≥100,000 cells/mm3;",
          "match_result": "positive",
          "comment": "The patient's platelets count is 110,000 cells/mm3, which is greater than the required 100,000 cells/mm3 mentioned in the criterion. Therefore, the patient meets the platelets criterion for the clinical trial."
        },
        {
          "id": 13,
          "type": "inclusion",
          "criterion": "Hemoglobin ≥10.0 g/dL;",
          "match_result": "positive",
          "comment": "The patient's Hemoglobin level is 11.0 g/dL which is greater than the required 10.0 g/dL mentioned in the criterion. Therefore, the patient meets the criterion of 'Hemoglobin ≥10.0 g/dL'."
        },
        {
          "id": 14,
          "type": "inclusion",
          "criterion": "Bilirubin ≤1.5 x ULN;",
          "match_result": "positive",
          "comment": "The patient's Total Bilirubin level is 1.2 x ULN, which meets the criterion of Bilirubin ≤1.5 x ULN. Therefore, the patient profile matches the Bilirubin criterion specified in the clinical trial."
        },
        {
          "id": 15,
          "type": "inclusion",
          "criterion": "AST (also known as SGOT) and ALT (also known as SGPT) ≤2.5 x ULN (≤5.0 x ULN if hepatic metastases).",
          "match_result": "positive",
          "comment": "The patient's AST (SGOT) and ALT (SGPT) levels are within normal limits, meeting the criterion of AST and ALT ≤2.5 x ULN. Therefore, the patient meets this specific criterion for the clinical trial."
        },
        {
          "id": 16,
          "type": "inclusion",
          "criterion": "Female subjects must be postmenopausal (defined as 12 months of amenorrhea following last menses), or they or their partners must be surgically sterile, or must agree to use effective contraception while receiving study treatment and for at least 3 months thereafter. The definition of effective contraception will be based on the judgment of the investigator using following criteria:",
          "match_result": "neutral",
          "comment": "More information is needed from the Patient profile to determine if this patient meets the criterion. The patient profile does not provide explicit information regarding the postmenopausal status, surgical sterilization, or contraceptive use, which are essential criteria for this clinical trial."
        },
        {
          "id": 17,
          "type": "inclusion",
          "criterion": "All female subjects with reproductive potential must have a negative pregnancy test (serum or urine) prior to starting study treatment;",
          "match_result": "neutral",
          "comment": "The patient profile does not provide information regarding the pregnancy test, which is required in the clinical trial criterion. Further details on the pregnancy status of the patient are needed to determine if this criterion is met."
        },
        {
          "id": 18,
          "type": "inclusion",
          "criterion": "Male subjects or their female partners must be surgically sterile or must agree to use effective contraception while receiving study treatment and for at least 3 months thereafter. The definition of effective contraception will be based on the judgment of the investigator. Or female partners must be postmenopausal (defined as 12 months of amenorrhea following last menses);",
          "match_result": "neutral",
          "comment": "The patient profile does not provide explicit information on the surgical sterility or contraception status of the male subject or their female partner. Further details are required to determine if this criterion is met."
        },
        {
          "id": 19,
          "type": "inclusion",
          "criterion": "Willing and able to comply with study scheduled visits, treatment plans, laboratory tests, and other study procedures.",
          "match_result": "positive",
          "comment": "The patient is willing and able to comply with study scheduled visits, treatment plans, laboratory tests, and other study procedures as there is no indication in the profile suggesting otherwise. Therefore, the criterion is met."
        }
      ],
      "embedding_score": 1
    }
  ],
  "ranked_sql_trials": [
    "NCT04027647"
  ]
}